WeTrials
Recruiting

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

What is this study?

This study tests a personalized treatment for advanced cancers where standard therapies have not worked. Researchers take your white blood cells, update them in a lab to target your specific tumor, and return them to help your body fight the cancer.

Who can participate?

You may be eligible if you have certain types of advanced solid tumors that have spread and have not responded to standard treatments. You must also meet specific health requirements and not have active infections or certain other conditions.

What will happen?

You will undergo screening tests and give blood cells through a special procedure called leukapheresis. After your cells are modified in the lab, you will stay in the hospital to receive the modified cells along with supportive medications.

Where and when?

This study is currently recruiting participants in Bethesda, Maryland, United States.

Key Points
  • 1Uses your own modified immune cells to fight your cancer
  • 2Involves a hospital stay for treatment and recovery
  • 3Requires regular follow-up visits over the course of several years

Related video

NCI: Steven Rosenberg explains immunotherapy research (background)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Endocrine TumorsNon-Small Cell Lung CancerOvarian CancerBreast CancerGastrointestinal/Genitourinary CancersNeuroendocrine TumorsMultiple Myeloma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.